Antibacterial drug development in the post-antibiotic era: a brief analysis of FDA approvals from 2018 to 2026

Antimicrobial resistance is a pressing global health threat, yet the state of the antibacterial pipeline is frequently judged by approval counts alone—a metric that can obscure whether new products represent genuine pharmacological innovation. This mini review examines the antibacterial-containing agents approved by the U.S. Food and Drug Administration (FDA) between 2018 and the first half of 2026, drawing on the FDA’s annual novel-drug approval reports, the corresponding approved product labels, and the primary literature. Over this period, 18 antibacterial-containing agents were approved—fewer than 5% of all FDA approvals—of which 15 are are intended for systemic therapy. To move beyond a simple count, we classify these approvals using an innovation framework defined by mechanism of action, chemical class, molecular target, bacterial entry strategy, protective-combination logic, and formulation design. Results show that the post-2018 record is dominated by incremental optimisation of established classes (tetracyclines, aminoglycosides) and by protective β-lactam/β-lactamase-inhibitor combinations. Strong discovery-relevant innovations remain the exception: two new chemical classes that act through distinct binding modes on validated topoisomerase targets (gepotidacin and zoliflodacin), the first pleuromutilin approved for systemic use (lefamulin), and a new bacterial entry strategy within an established class (cefiderocol). We conclude that the post-2018 record shows a partial recovery in FDA approval numbers that has not been accompanied by a proportionate expansion of the chemical and mechanistic space of approved products; approval counts alone cannot demonstrate a renewal of antibacterial discovery. We argue that a pharmacology-centred reading of the approval record is more informative than the count itself.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-18
DOI
https://doi.org/10.3389/fphar.2026.1974679
Primary Topic
Antibiotic Resistance in Bacteria
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Antibacterial drug development in the post-antibiotic era: a brief analysis of FDA approvals from 2018 to 2026

Javier Campanini-Salinas, David Vásquez, Juan Andrades-Lagos
1 links
Frontiers in Pharmacology
Antibiotic Resistance in Bacteria
article

Antibacterial drug development in the post-antibiotic era: a brief analysis of FDA approvals from 2018 to 2026

Javier Campanini-Salinas, David Vásquez, Juan Andrades-Lagos
article en

Abstract

Antimicrobial resistance is a pressing global health threat, yet the state of the antibacterial pipeline is frequently judged by approval counts alone—a metric that can obscure whether new products represent genuine pharmacological innovation. This mini review examines the antibacterial-containing agents approved by the U.S. Food and Drug Administration (FDA) between 2018 and the first half of 2026, drawing on the FDA’s annual novel-drug approval reports, the corresponding approved product labels, and the primary literature. Over this period, 18 antibacterial-containing agents were approved—fewer than 5% of all FDA approvals—of which 15 are are intended for systemic therapy. To move beyond a simple count, we classify these approvals using an innovation framework defined by mechanism of action, chemical class, molecular target, bacterial entry strategy, protective-combination logic, and formulation design. Results show that the post-2018 record is dominated by incremental optimisation of established classes (tetracyclines, aminoglycosides) and by protective β-lactam/β-lactamase-inhibitor combinations. Strong discovery-relevant innovations remain the exception: two new chemical classes that act through distinct binding modes on validated topoisomerase targets (gepotidacin and zoliflodacin), the first pleuromutilin approved for systemic use (lefamulin), and a new bacterial entry strategy within an established class (cefiderocol). We conclude that the post-2018 record shows a partial recovery in FDA approval numbers that has not been accompanied by a proportionate expansion of the chemical and mechanistic space of approved products; approval counts alone cannot demonstrate a renewal of antibacterial discovery. We argue that a pharmacology-centred reading of the approval record is more informative than the count itself.

Frontiers in PharmacologyVol. 17
Universidad San Sebastián (CL), University of Chile (CL)
Good health and well-being
Antibiotic Resistance in Bacteria
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon